PYRIDAZINONES AND METHODS OF USE THEREOF

(19)

(11)

EP 3 852 533 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	17.07.2024 Bulletin 2024/29

(45)	Mention of the grant of the patent:
	28.02.2024 Bulletin 2024/09

(21)	Application number: 19863481.8

(22)	Date of filing: 18.09.2019

(51)

International Patent Classification (IPC):

C07D 471/04^(2006.01)
A61P 3/10^(2006.01)
A61P 13/12^(2006.01)
A61P 25/22^(2006.01)
A61P 27/02^(2006.01)
A61K 31/519^(2006.01)

A61P 3/04^(2006.01)
A61P 9/12^(2006.01)
A61P 25/04^(2006.01)
A61P 25/24^(2006.01)
A61P 35/00^(2006.01)
A61K 31/4375^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61P 13/12; C07D 471/04; A61P 25/22; A61P 25/24; A61P 35/00; A61P 9/12; A61P 27/02; A61P 25/04; A61P 3/10; A61P 3/04

(86)	International application number:
	PCT/US2019/051680

(87)	International publication number:
	WO 2020/061162 (26.03.2020 Gazette 2020/13)

(54)	PYRIDAZINONES AND METHODS OF USE THEREOF PYRIDAZINONE UND VERFAHREN ZUR VERWENDUNG DAVON PYRIDAZINONES ET LEURS PROCÉDÉS D'UTILISATION

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

18.09.2018 US 201862732728 P
17.12.2018 US 201862780553 P

(43)	Date of publication of application:
	28.07.2021 Bulletin 2021/30

(60)	Divisional application:
	24155641.4

(73)	Proprietor: GFB (ABC), LLC
	Foxboro, MA 02035 (US)

(72)	Inventors:
	LEDEBOER, Mark, W. Acton, MA 01720 (US) DANIELS, Matthew, H. Somerville, MA 02145 (US) YU, Maolin West Roxbury, Massachusetts 02132 (US) HARMANGE, Jean-Christophe, P. Andorer, MA 01810 (US)

(74)	Representative: HGF
	HGF Limited 1 City Walk Leeds LS11 9DX Leeds LS11 9DX (GB)

(56)

References cited: :

WO-A1-2020/191056
WO-A2-2019/055966
US-B2- 9 139 573

WO-A1-2020/210639
US-A1- 2016 046 624

STRAPPAGHETTI ET AL.: "Adenosine receptors: synthesis, structure-activity relationships and biological activity of new 6-amino purine derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, June 1998 (1998-06-01), pages 501 - 508, XP026884003, DOI: 10.1016/S0223-5234(98)80050-0
MILLER ET AL.: "Identification of ML204, a Novel Potent Antagonist That Selectively Modulates Native TRPC4/C5 Ion Channels", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, 27 July 2011 (2011-07-27), pages 33436 - 33446, XP055053586, DOI: 10.1074/jbc.M111.274167

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).